{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:41Z","timestamp":1791460841512,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8137349"],"award-info":[{"award-number":["8137349"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373495"],"award-info":[{"award-number":["81373495"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["KJ2017A202"],"award-info":[{"award-number":["KJ2017A202"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["2017zhyx04"],"award-info":[{"award-number":["2017zhyx04"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.intimp.2019.105911","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T06:19:53Z","timestamp":1572243593000},"page":"105911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3"],"prefix":"10.1016","volume":"77","author":[{"given":"Yuan-Yuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Xiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105911_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2019.105911_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2019.105911_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.intimp.2019.105911_bb0020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2019.105911_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.intimp.2019.105911_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2019.105911_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0035-1550057","article-title":"Resolution of liver fibrosis: basic mechanisms and clinical relevance","volume":"35","author":"Ramachandran","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.intimp.2019.105911_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2019.105911_bb0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2019.105911_bb0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/gut.2005.088690","article-title":"Emerging insights into transforming growth factor Smad signal in hepatic fibrogenesis","volume":"56","author":"Inagaki","year":"2007","journal-title":"GUT"},{"key":"10.1016\/j.intimp.2019.105911_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.redox.2014.01.012","article-title":"NADPH oxidase-dependent redox signaling in TGF-\u03b2-mediated fibrotic responses","volume":"2","author":"Jiang","year":"2014","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2019.105911_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/cancers10060183","article-title":"Clinico-pathological importance of TGF-\u03b2\/phospho-Smad signaling during human hepatic fibrocarcinogenesis","volume":"10","author":"Yoshida","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2019.105911_bb0065","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3892\/ijo.2014.2552","article-title":"TGF-\u03b2\/Smad signaling during hepatic fibro-carcinogenesis (review)","volume":"45","author":"Yoshida","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2019.105911_bb0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-\u03b2 as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2019.105911_bb0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00535-016-1190-4","article-title":"Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights","volume":"51","author":"Greuter","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.intimp.2019.105911_bb0080","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2019.105911_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2019.105911_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.intimp.2019.105911_bb0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2019.105911_bb0100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.intimp.2019.105911_bb0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2019.105911_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsbmb.2017.01.010","article-title":"Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis","volume":"168","author":"Comeglio","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.intimp.2019.105911_bb0115","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.intimp.2019.105911_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01344","article-title":"Inositol-requiring enzyme 1 alpha endoribonuclease specific inhibitor STF-083010 alleviates carbon tetrachloride induced liver injury and liver fibrosis in mice","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2019.105911_bb0125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.taap.2012.11.007","article-title":"Phenylbutyric acid protects against carbon tetrachloride-induced hepatic fibrogenesis in mice","volume":"266","author":"Wang","year":"2013","journal-title":"Toxicol APPL Pharm"},{"key":"10.1016\/j.intimp.2019.105911_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol Appl Pharm"},{"key":"10.1016\/j.intimp.2019.105911_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2019.105911_bb0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrgastro.2013.244","article-title":"Hepatic stellate cells hold the key to liver fibrosis","volume":"11","author":"Ray","year":"2014","journal-title":"Nat Rev Gastro Hepat"},{"key":"10.1016\/j.intimp.2019.105911_bb0145","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1096\/fj.201801699R","article-title":"The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction","volume":"33","author":"Li","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2019.105911_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph11040104","article-title":"Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2019.105911_bb0155","article-title":"Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2018","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2019.105911_bb0160","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet, The"},{"key":"10.1016\/j.intimp.2019.105911_bb0165","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.intimp.2019.105911_bb0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","article-title":"Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice","volume":"6","author":"Jouihan","year":"2017","journal-title":"MOL METAB"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919315474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919315474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:49:14Z","timestamp":1778820554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919315474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"alternative-id":["S1567576919315474"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105911","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105911"}}